{
    "clinical_study": {
        "@rank": "11694", 
        "acronym": "OLIMPIC", 
        "arm_group": {
            "arm_group_label": "Ranibizumab", 
            "arm_group_type": "Experimental", 
            "description": "patients treated with ranibizumab 0,5 mg/0,05ml intravitreal injection"
        }, 
        "brief_summary": {
            "textblock": "The  primary objective of the study is to investigate current criteria driving re-treatment\n      in patients affected by CNV secondary to PM and experiencing a relapse of the disease after\n      the first administration of ranibizumab."
        }, 
        "brief_title": "A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Choroidal Neovascularization Secondary to Pathologic Myopia", 
        "condition_browse": {
            "mesh_term": [
                "Myopia", 
                "Neovascularization, Pathologic", 
                "Vision, Low", 
                "Vision Disorders", 
                "Choroidal Neovascularization"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Written informed consent given before any study related procedure is performed\n\n          -  Diagnosis of active CNV secondary to PM confirmed by complete ocular examination in\n             the affected eye(s) using the following criteria:\n\n          -  Presence of high myopia greater than -6D of spherical equivalence\n\n          -  Presence of posterior changes compatible with pathologic myopia (any signs of\n             attenuation of retinal pigment epithelium (RPE) and choroids, mottling of the RPE,\n             tilted disc, geographic atrophy of RPE, Fuchs spots, posterior staphyloma, submacular\n             hemorrhage, lacquer cracks) detected by fundus ophthalmoscopy and fundus photography\n\n          -  Presence of active leakage from CNV observed through fluorescein angiography (FAG)\n\n          -  Presence of intra or subretinal fluid demonstrated by Optical Coherence Tomography\n             (OCT)\n\n          -  BCVA > 24 letters and < 78 letters tested at 4 meters staring distance using\n             ETDRS-like visual acuity chart\n\n          -  Visual loss must be only due to the presence of any eligible types of CNV related to\n             PM based on clinical ocular findings, FAG and OCT. (Also patients that have for\n             example 20/60 as their best visual acuity due to PM in their history and have\n             additional vision loss due to CNV lesion can be included)\n\n        EXCLUSION CRITERIA:\n\n          -  Patients with inability to comply with study related procedures\n\n          -  Pregnant or nursing (lactating) women and women of childbearing potential UNLESS\n             using effective contraception during treatment\n\n          -  Presence of confirmed systolic blood pressure > 150 mmHg or diastolic > 90 mmHg at\n             the time of enrollment\n\n          -  History of stroke\n\n          -  Any type of advanced, severe or unstable medical condition or its treatment that\n             could significantly bias the assessment of clinical status and interfere with primary\n             and/or secondary outcome evaluations or put the patient at risk\n\n          -  Presence of active infectious disease or intra-ocular inflammation in either eye at\n             the time of enrollment\n\n          -  Ocular disorders in the study eye that may confound interpretation of study results,\n             compromise visual acuity or require medical or surgical intervention during the\n             12-month study period (including retinal detachment, cataract and pre-retinal\n             membrane of the macula)\n\n          -  History of pan-retinal or focal/grid laser photocoagulation with involvement of the\n             macular area in the study eye at any time\n\n          -  History of intraocular treatment with any anti-vascular endothelial growth factor\n             (VEGF), verteporfin photodynamic therapy (vPDT) and any intra-ocular surgery or\n             corticosteroid administration within one month before study entrance\n\n          -  Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation\n\n          -  Simultaneous participation in a study that includes administration of any\n             investigational drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034006", 
            "org_study_id": "CRFB002FIT01"
        }, 
        "intervention": {
            "arm_group_label": "Ranibizumab", 
            "description": "All patients will receive a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per CHMP approval. Further injections might be required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, will be evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment is allowed provided at least 14 days of intercurrence.", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Angiogenesis Inhibitors", 
                "Angiogenesis Modulating Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pathological myopia", 
            "choroidal neovascularization", 
            "ranibizumab", 
            "mono-bilateral", 
            "poor visual acuity", 
            "retinal disease", 
            "eye disease", 
            "Angiogenesis Inhibitors", 
            "Angiogenesis Modulating Agents"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Casale Monferrato", 
                        "country": "Italy", 
                        "state": "AL", 
                        "zip": "15033"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "state": "AN", 
                        "zip": "60126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "BA", 
                        "zip": "70124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Desenzano del Garda", 
                        "country": "Italy", 
                        "state": "BS", 
                        "zip": "25015"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bolzano", 
                        "country": "Italy", 
                        "state": "BZ", 
                        "zip": "39100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "state": "CA", 
                        "zip": "09124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chieti", 
                        "country": "Italy", 
                        "state": "CH", 
                        "zip": "66100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Como", 
                        "country": "Italy", 
                        "state": "CO", 
                        "zip": "22100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy", 
                        "state": "CT", 
                        "zip": "95123"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catanzaro", 
                        "country": "Italy", 
                        "state": "CZ", 
                        "zip": "88100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI", 
                        "zip": "50134"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "GE", 
                        "zip": "16132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rapallo", 
                        "country": "Italy", 
                        "state": "GE", 
                        "zip": "16035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terracina", 
                        "country": "Italy", 
                        "state": "LT", 
                        "zip": "04019"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20157"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "PA", 
                        "zip": "90127"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perugia", 
                        "country": "Italy", 
                        "state": "PG", 
                        "zip": "06100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "PI", 
                        "zip": "56124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy", 
                        "state": "PR", 
                        "zip": "43100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00161"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00144"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00198"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy", 
                        "state": "SI", 
                        "zip": "53100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trieste", 
                        "country": "Italy", 
                        "state": "TS", 
                        "zip": "34129"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Conegliano", 
                        "country": "Italy", 
                        "state": "TV", 
                        "zip": "31015"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "state": "UD", 
                        "zip": "33100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varese", 
                        "country": "Italy", 
                        "state": "VA", 
                        "zip": "21100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Negrar", 
                        "country": "Italy", 
                        "state": "VR", 
                        "zip": "37024"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to investigate current criteria driving re-treatment in patients affected by CNV secondary to PM and experiencing a relapse of the disease after the first administration of ranibizumab. The criteria for re-treatment may consist in patient subjectivity or a clinical decision (described through clinical examination, BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Descriptive statistic on the FAS population will be provided.\nThe proportion of patients who need re-treatment will be displayed together with a 95% confidence interval. The criteria for re-treatment will be summarized, presenting, for each, frequencies, percentages and 95% CI.", 
            "measure": "Describe current criteria driving re-treatment in patients experiencing a relapse after first ranibizumab injection", 
            "safety_issue": "No", 
            "time_frame": "Baseline to month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034006"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the mean changes in BCVA at 6M and 12M versus baseline. Summary statistics for BCVA will be provided for values at baseline and at each assessment and for changes versus baseline at each assessment. Results will be reported overall and separately for the sub-group of patients who need vs. not the re-treatment. A paired test of BCVA at 6 and 12 months vs. baseline will be also provided on all patients. An exploratory analysis of BCVA changes by class of disease duration, gender, age at entry, diopters and relevant medical conditions will be also provided.", 
                "measure": "Visual acuity changes", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 6, month 12"
            }, 
            {
                "description": "To evaluate the mean number of ranibizumab injections by patient/year. The number and percentage of patients who need re-treatment will be provided.", 
                "measure": "mean number of ranibizumab injection", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 12"
            }, 
            {
                "description": "Time to re-treatment, defined as time in days from the data of first dose of ranibizumab to the date of re-treatment, will be evaluated. Descriptive statistics will be provided. A Kaplan-Meier curve will also be shown.\nThe relationship between patient baseline characteristics and the need for re-treatment will be explored by means of logistic regression analysis", 
                "measure": "time to relapse / retratment", 
                "safety_issue": "No", 
                "time_frame": "baseline to month 12"
            }, 
            {
                "description": "AEs will be summarized as following: n\u00b0 and % of patients having any AE, an ocular AE, a non-ocular AE, an AE in each primary system organ class, or with at least one serious ocular or non-ocular AE.\nSummary tables will be presented: overall and by gender, for the subset of AEs suspected to be treatment related.\nDeaths, SAEs, and AEs leading to discontinuation of investigational treatment will be listed separately and, if appropriate, summarized by primary system organ class and preferred term.\nIOP, vital signs measurements and laboratory data, where available, will be summarized with descriptive statistics of actual values and changes from baseline values. Summary tables will be presented overall and by gender.\nThe incidence rates of notable vital sign abnormalities will be also provided.", 
                "measure": "Number and percentage of patients having ocular or systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to month 12"
            }, 
            {
                "description": "To evaluate changes in the quality of life after ranibizumab injection, by means of IVI Questionnaire, a 32-item questionnaire developed to measure the impact of vision impairment on daily activities in five domains. Domain scores and total score will be summarized descriptively in actual values and changes versus baseline at each assessment.\nThe Burden of Illness and Health Resources Utilization questionnaire will also be used ro gain information on resource consumption and burden for the patient and relatives to the disease. Summary statistic will be provided for each item.", 
                "measure": "Evaluation of patient quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 2, month 12"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}